New PET scan probe could sharpen lung cancer detection
NCT ID NCT07508852
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a new radioactive probe called PFD3, used with a PET/CT scan, to see if it can better find and assess small cell lung cancer (SCLC) by targeting a protein called DLL3 found on cancer cells. About 30 adults with SCLC will receive both a standard FDG scan and the new PFD3 scan to compare their accuracy. The goal is to improve diagnosis and monitoring of this aggressive cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
68Ga-PFD3 (a radioactive probe for PET/CT imaging)
What this could lead to
If successful, this could provide a more accurate way to diagnose and monitor small cell lung cancer, potentially guiding better treatment decisions.
What could go wrong
This is an early-phase trial with only 30 participants, so results may not apply to everyone. The probe's safety and effectiveness are still being tested.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER ( SCLC ) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking university first hospital nuclear medicine
RECRUITINGBeijing, Beijing Municipality, 100034, China
Contact Phone: •••-•••-•••• Email: •••••@•••••